JP2021535164A5 - - Google Patents

Info

Publication number
JP2021535164A5
JP2021535164A5 JP2021511547A JP2021511547A JP2021535164A5 JP 2021535164 A5 JP2021535164 A5 JP 2021535164A5 JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021535164 A5 JP2021535164 A5 JP 2021535164A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021511547A
Other languages
English (en)
Japanese (ja)
Other versions
JP7447089B2 (ja
JP2021535164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049118 external-priority patent/WO2020047447A1/en
Publication of JP2021535164A publication Critical patent/JP2021535164A/ja
Publication of JP2021535164A5 publication Critical patent/JP2021535164A5/ja
Priority to JP2024028682A priority Critical patent/JP7825650B2/ja
Application granted granted Critical
Publication of JP7447089B2 publication Critical patent/JP7447089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021511547A 2018-08-31 2019-08-30 心筋サルコメア阻害剤 Active JP7447089B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024028682A JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726162P 2018-08-31 2018-08-31
US62/726,162 2018-08-31
PCT/US2019/049118 WO2020047447A1 (en) 2018-08-31 2019-08-30 Cardiac sarcomere inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024028682A Division JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Publications (3)

Publication Number Publication Date
JP2021535164A JP2021535164A (ja) 2021-12-16
JP2021535164A5 true JP2021535164A5 (enExample) 2022-10-18
JP7447089B2 JP7447089B2 (ja) 2024-03-11

Family

ID=67953902

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511547A Active JP7447089B2 (ja) 2018-08-31 2019-08-30 心筋サルコメア阻害剤
JP2024028682A Active JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024028682A Active JP7825650B2 (ja) 2018-08-31 2024-02-28 心筋サルコメア阻害剤

Country Status (21)

Country Link
US (4) US11414424B2 (enExample)
EP (1) EP3843842A1 (enExample)
JP (2) JP7447089B2 (enExample)
CN (2) CN112867539B (enExample)
AR (1) AR116283A1 (enExample)
AU (1) AU2019328556B2 (enExample)
BR (1) BR112021003496A2 (enExample)
CA (1) CA3110237A1 (enExample)
CL (1) CL2021000481A1 (enExample)
CO (1) CO2021003115A2 (enExample)
EA (1) EA202190657A1 (enExample)
EC (1) ECSP21016009A (enExample)
IL (2) IL315709A (enExample)
MA (1) MA53491A (enExample)
MX (1) MX2021002199A (enExample)
NZ (1) NZ773016A (enExample)
PH (1) PH12021550400A1 (enExample)
SG (1) SG11202101769YA (enExample)
TW (1) TWI848972B (enExample)
UY (1) UY38358A (enExample)
WO (1) WO2020047447A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN116234546A (zh) * 2020-03-11 2023-06-06 嘉兴优博生物技术有限公司 Gpx4抑制剂、其药物组合物及它们在治疗gpx4介导的疾病中的用途
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
WO2022057849A1 (zh) * 2020-09-17 2022-03-24 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
EP4249474A4 (en) * 2020-11-20 2024-04-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
KR20240015622A (ko) * 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN119789856A (zh) 2022-04-26 2025-04-08 迈奥卡迪亚公司 施用肌球蛋白抑制剂的方法
CN119998292A (zh) 2022-09-02 2025-05-13 赛特凯恩蒂克公司 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
CN122070481A (zh) 2023-11-01 2026-05-19 百时美施贵宝公司 基于蛋白质水平用肌球蛋白抑制剂进行治疗的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5919785A (en) * 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR100595926B1 (ko) 1998-01-26 2006-07-05 웨인 웨스터만 수동 입력 통합 방법 및 장치
US20030158186A1 (en) 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US20070155713A1 (en) * 2003-04-21 2007-07-05 Rena Nishizawa Nitrogen-containing heterocyclic compounds and use thereof
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
MX2007006230A (es) * 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
SG11201705928XA (en) 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
CN108430997B (zh) 2015-12-17 2021-06-04 先正达参股股份有限公司 杀微生物的噁二唑衍生物
US20190364899A1 (en) 2015-12-18 2019-12-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018089433A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
CA3157629A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4249474A4 (en) 2020-11-20 2024-04-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN116507621B (zh) 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN119998292A (zh) 2022-09-02 2025-05-13 赛特凯恩蒂克公司 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式

Similar Documents

Publication Publication Date Title
JP2021529185A5 (enExample)
JP2021529746A5 (enExample)
JP2021511331A5 (enExample)
JP2024508526A5 (enExample)
JP2021516240A5 (enExample)
JP2002520309A5 (enExample)
JP2009535393A5 (enExample)
JP2022510313A5 (enExample)
US11306102B2 (en) 1,3-di-substituted ketene compound and application thereof
JP2002080453A (ja) 選択的シクロオキシゲナーゼ−2阻害物質となる置換ピリジン
JP5734532B2 (ja) アゾールベンゼン誘導体
JP2004534035A5 (enExample)
RU2018120242A (ru) Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов
JP2012505891A5 (enExample)
RU2003112610A (ru) Производные пиразола для лечения вирксных заболеваний
JP2019531320A5 (enExample)
JP2008531520A5 (enExample)
JP2006056881A5 (enExample)
JP2022534902A5 (enExample)
RU2014107000A (ru) Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств
JP2023518775A5 (enExample)
JP2022537350A5 (enExample)
JP2016510810A5 (enExample)
JP2010504322A5 (enExample)
JP2022544803A5 (enExample)